Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported financial results for the third quarter ended September 30, 2009. Optimer reported a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2008 of $9.2 million, or $0.31 per share. Research and development expenses in the third quarter of 2009 were $7.2 million, compared to $7.9 million in the third quarter of 2008. The decrease was primarily due to the completion of the Pruvel(TM)(prulifloxacin) Phase 3 trials. The decrease was partially offset by an increase in expenses to prepare regulatory filings related to fidaxomicin and Pruvel.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

As of September 30, 2009, Optimer held cash, cash equivalents and short-term investments of $42.5 million.

"It's been another strong quarter for Optimer, marked by significant interaction with the medical community on the Phase 3 data profiling the characteristics and attributes of fidaxomicin and Pruvel," said Michael N. Chang, Ph.D., Optimer's President and Chief Executive Officer. "Additional data from the North American Phase 3 fidaxomicin trial were recently presented at the ICAAC and IDSA medical conferences further demonstrating why we believe fidaxomicin has the potential to be the optimal treatment for CDI."

Corporate Updates

  • Following discussions with the FDA, Optimer has elevated global cure to a secondary endpoint from an exploratory endpoint in the second Phase 3 fidaxomicin trial. Given the
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., , HOPKINTON, Mass., Dec. 3 /PRNewswire-... CALP ), a leading provider of tools and services...day introduced Living Image 4.0 software for IVIS&...re drives the more than 800 Caliper IVIS systems c...ng Image 4.0 features advanced spectral unmixing t...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 ...arch report is available in its catalogue: ,, ...tive ,, http://www.reportlinker.com/p0164368/...tive.html ,, Incubators are the most critical... research, and other applications for providing a ...
(Date:12/2/2009)..., , CALGARY, Dec. 2 /PRNewswire-Firs...the "Company") (TSX:ONC; NASDAQ: ONCY ) announced ...nced unit offering, the underwriters have exercise...d an additional 637,500 units. Each unit is compri...purchase warrant, and was sold at a price of US$3....
(Date:12/2/2009)..., , SINGAPORE, Dec. 2 ...on its novel oral JAK2 inhibitor, SB1518, at The A...and Exposition in New Orleans. ,, Data will be ... dose-escalation trial of SB1518 detailing its saf...mic (PK/PD) profile in dose levels ranging from 10...
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... The American Filtration ... 22nd Annual Conference, May 4-7, 2009 at the Sher... Minneapolis, MN (PRWEB) April 7, 200...ety (AFS) will be holding its 22nd Annual Confere...ngton Minnesota. Dr. David Y.H. Pui, Distinguishe...
... SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceu...) today announced the appointment of the U.S. life...to its Board of Directors. , Mr van den Broek ...LC, a,U.S. based fund manager with an investment e...ies. HSMR Advisors has held a position on the Pha...
...TUCSON, Ariz., and GILROY, Calif., April 6 The De... College of Medicine and OmegaGenesis, Inc., annou...dies to address diabetic foot ulcers. , , The a...al remedies and to identify effective ways to prov...nals and patients globally. , , Diabetic foot ulc...
Other Biology Technology:University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 2University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 3New Pharmaxis Board Appointment 2The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers 2The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers 3The University of Arizona College of Medicine and OmegaGenesis Announce Collaboration Agreement to Address Diabetic Foot Ulcers 4
(Date:12/3/2009)... Forest dwellers must be included in the design o...to avoid a humanitarian crisis, according to a sci...day in Nature , Dr Simon Lewis argues that at lea...at Copenhagen, known as REDD (Reducing Emissions f... to forest dwellers directly, and their property r...
(Date:12/2/2009)... , PHILADELPHIA Children exposed to secondhand c...g lung cancer in adulthood, even if they never smo...Cancer Epidemiology, Biomarkers & Prevention , a j...arch, as part of a special tobacco focus in the De...000 Americans will be diagnosed with lung cancer; ...
(Date:12/2/2009)... , PHILADELPHIA Mexican-American adolescents exp...e likely to pick up the habit themselves, and this...ed with smoking initiation, according to new study... smoking in the United States and highlights the g...ion Framework Convention on Tobacco Control, which...
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Microsoft Rogue Internet Pharmacy Problem Fixed 3F Not So Fast Say Researchers 54512 1Microsoft Rogue Internet Pharmacy Problem Fixed 3F Not So Fast Say Researchers 54512 2Orchids and fungi partners for life 9571 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 2
... phage display technique successful in identifying...sistance , A simple, harmless virus might hold th...ent of HIV and anti-viral drugs, UCI chemical biol...ompounds that can outmaneuver a virus, effort to m...ewski employed this virus, called a bacteriophage,...
...ritical lock and key mechanism that allows the fin...ation has been identified by a University of Calif... research that promises to lead to a new way to ha...ply. , The research team led by Judith Varner, Ph....member of the Rebecca and John Moores UCSD Cancer ...
...rug first used to reduce the risk of stomach ulcer...fers an alternative to surgery after miscarriage, ...l Institute of Child Health and Human Development ...earch institutions. , The study appears in the Au...The drug, misoprostol, has been used to reduce the...
Other Biology News:Harmless virus may hold key to more effective HIV drug discovery 2Unexpected lock and key mechanism found for the assembly of tumor blood vessels 2Unexpected lock and key mechanism found for the assembly of tumor blood vessels 3Sleeping Sickness Epidemic Spreading in Uganda 2Sleeping Sickness Epidemic Spreading in Uganda 3Sleeping Sickness Epidemic Spreading in Uganda 4
Carp Vitellogenin ELISA System from GE Healthcare, formerly Amersham Biosciences
...ts provide rapid and efficient removal of short pr...and salts from PCR products (Figure 1). The simple...o Binding Buffer options for fragments >100 bp or ...n or 96-well plate format , takes ,Two proprieta...
...ystem with Gateway™ Technology is designed t...aining the polyhedrin promoter. The expression cas...cmid DNA) by site-specific transposition (Tn7) in ...id DNA is then used for transfection and expressio...
GIBCO Earles Balanced Salt Solution (EBSS) (1X); liquid from Invitrogen
Biology Products: